WHY JAPAN
Japan is a top-three healthcare market in the world, and home to many top pharma companies with an appetite for Nordic innovations.
Japan is an extremely large market – with 125 million people, it is the 3rd
largest healthcare market in the world, and home to some of the top global healthcare companies in the world.
As Japan has limited amount of startups, Japanese companies increasingly rely on overseas startups to boost innovation.
The country has a comprehensive universal healthcare system, and patients are free to choose their healthcare providers. The medical expenditures have increased in Japan over 30% since 2000, and now constitute 11% of GDP.
Examples of the strong track record of Japanese investment in the Nordic life science sector:
- Eisai’s investment in Sweden’s Bioarctic lead to world’s first fully FDA approved fully approved Alzheimer’s drug in 2023
- Fujifilm USD 1.6 billion investment to expand advanced manufacturing in Denmark.
